GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Indofarma Tbk (ISX:INAF) » Definitions » Retained Earnings

PT Indofarma Tbk (ISX:INAF) Retained Earnings : Rp-807,996 Mil (As of Sep. 2023)


View and export this data going back to 2001. Start your Free Trial

What is PT Indofarma Tbk Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. PT Indofarma Tbk's retained earnings for the quarter that ended in Sep. 2023 was Rp-807,996 Mil.

PT Indofarma Tbk's quarterly retained earnings declined from Mar. 2023 (Rp-678,092 Mil) to Jun. 2023 (Rp-736,642 Mil) and declined from Jun. 2023 (Rp-736,642 Mil) to Sep. 2023 (Rp-807,996 Mil).

PT Indofarma Tbk's annual retained earnings declined from Dec. 2020 (Rp-150,252 Mil) to Dec. 2021 (Rp-187,833 Mil) and declined from Dec. 2021 (Rp-187,833 Mil) to Dec. 2022 (Rp-616,296 Mil).


PT Indofarma Tbk Retained Earnings Historical Data

The historical data trend for PT Indofarma Tbk's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Indofarma Tbk Retained Earnings Chart

PT Indofarma Tbk Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87,261.12 -79,300.15 -150,252.02 -187,832.66 -616,295.61

PT Indofarma Tbk Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -370,942.85 -616,295.61 -678,092.11 -736,641.65 -807,995.50

PT Indofarma Tbk Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


PT Indofarma Tbk  (ISX:INAF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


PT Indofarma Tbk (ISX:INAF) Business Description

Traded in Other Exchanges
N/A
Address
Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others, Pharmaceutical Engineering, and Aliansi Strategis Segment. The Medicine business segment includes drug production, marketing and distribution and sales. The Medical Device Segment includes medical devices and other products. The Pharmaceutical Engineering Segment includes the sale and maintenance of packaging machines for the pharmaceutical industry to external parties.

PT Indofarma Tbk (ISX:INAF) Headlines

No Headlines